Literature DB >> 15533540

It is possible to help smokers in early motivational stages to quit. The Inter99 study.

Charlotta Pisinger1, Jørgen Vestbo, Knut Borch-Johnsen, Torben Jørgensen.   

Abstract

BACKGROUND: In a population-based sample of smokers in early motivational stages, we found a high acceptance of smoking cessation groups.
METHODS: Inter99 is a randomized population-based intervention study, in Copenhagen, Denmark. Smokers in all motivational stages were included. All participants underwent a lifestyle consultation and 2,168 smokers in the high intensity intervention group were offered assistance to quit in smoking cessation groups.
RESULTS: Thirty-five percent were validated to be continuously abstinent at the end of the smoking cessation groups. Eighty-four percent of the smokers achieving sustained abstinence in our study had no serious plans to quit soon before the lifestyle consultation. Motivation to quit before the lifestyle consultation could not predict abstinence. Being a man, and having a job and at least 1 year of vocational training were predictors of abstinence in a multivariate model, whereas high nicotine dependence and living with a smoking spouse were predictors of failure.
CONCLUSION: High cessation rates were obtained in a population of heavy smokers with moderate nicotine dependence. It was possible to obtain sustained abstinence in smokers in early motivational stages. These smokers would probably not have been reached by traditional smoking campaigns.

Entities:  

Mesh:

Year:  2005        PMID: 15533540     DOI: 10.1016/j.ypmed.2004.06.011

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  26 in total

Review 1.  Managing smoking cessation.

Authors:  Paul Aveyard; Robert West
Journal:  BMJ       Date:  2007-07-07

2.  A group-randomized tobacco trial among 30 Pacific Northwest colleges: results from the Campus Health Action on Tobacco study.

Authors:  Beti Thompson; Dale McLerran; Jennifer C Livaudais; Gloria D Coronado
Journal:  Nicotine Tob Res       Date:  2010-05-06       Impact factor: 4.244

3.  Brief assessment of readiness to change tobacco use in treated youth.

Authors:  Tammy Chung; Stephen A Maisto; Anthony Mihalo; Christopher S Martin; Jack R Cornelius; Duncan B Clark
Journal:  J Subst Abuse Treat       Date:  2011-04-12

4.  Smoking cessation at the workplace: 1 year success of short seminars.

Authors:  Hp Hutter; H Moshammer; M Neuberger
Journal:  Int Arch Occup Environ Health       Date:  2005-08-23       Impact factor: 3.015

Review 5.  Group behaviour therapy programmes for smoking cessation.

Authors:  Lindsay F Stead; Allison J Carroll; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2017-03-31

6.  Parent quit attempts after counseling to reduce children's secondhand smoke exposure and promote cessation: main and moderating relationships.

Authors:  Sandy Liles; Melbourne F Hovell; Georg E Matt; Joy M Zakarian; Jennifer A Jones
Journal:  Nicotine Tob Res       Date:  2009-10-29       Impact factor: 4.244

7.  The role of nicotine replacement therapy in early quitting success.

Authors:  Nancy Amodei; R J Lamb
Journal:  Nicotine Tob Res       Date:  2009-11-06       Impact factor: 4.244

8.  Health decision making: lynchpin of evidence-based practice.

Authors:  Bonnie Spring
Journal:  Med Decis Making       Date:  2008-11-17       Impact factor: 2.583

9.  Smokers with bipolar disorder, other affective disorders, and no mental health conditions: Comparison of baseline characteristics and success at quitting in a large 12-month behavioral intervention randomized trial.

Authors:  Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker
Journal:  Drug Alcohol Depend       Date:  2018-10-10       Impact factor: 4.492

Review 10.  Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.

Authors:  Jon O Ebbert; Kirk D Wyatt; Ali Zirakzadeh; Michael V Burke; Jt Hays
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.